Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients

首次发布于 2013 年 3 月 18 日

The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects

计划入组 21 人 · 首次发布于 2008 年 10 月 7 日

Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients

计划入组 100 人 · 首次发布于 2006 年 8 月 29 日

phosphodiesterase inhibitors (Syntex)

Phosphodiesterase III inhibitors (VIVUS)

Phosphodiesterase inhibitor(Boehringer Ingelheim)

宝鸡韩勇9+9制药厂

9 METERS BIOPHARMA, INC.

United States

Lexaria Bioscience

United States

Cardurion to Present Phase 2 Results for PDE9 Inhibitor Tovinontrine in Both Major Types of Heart Failure

Cardurion Completes Enrollment in Phase 2 Trials for Novel Heart Failure Drug CRD-750

Advancements in Ocular Therapies: Updates on Dry Eye, AMD, and Myopia Management